A nanoparticle that carries a self-antigen, a molecule that blocks B cell activation, and a drug that boosts regulatory T cells works together to reduce autoimmune arthritis in mice by simultaneously calming two parts of the immune system.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether the combined presence of antigen, CD22 ligand, and rapamycin in a single nanoparticle consistently outperforms individual components across studies in suppressing autoimmunity.
A systematic review and meta-analysis comparing immune outcomes in all published studies using this nanoparticle platform versus versions lacking one component (antigen, CD22L, or rapamycin) in autoimmune mouse models, pooling effect sizes for Treg increase and antibody reduction.
Whether the full nanoparticle design causes greater immune suppression than versions missing one component.
A double-blind, randomized controlled trial in 80 K/BxN mice, randomized to four groups: full nanoparticle, nanoparticle without CD22L, without rapamycin, or without antigen, with primary outcomes: anti-GPI titers, Treg frequency, and arthritis score at day 30.
Whether the presence of all three components predicts stronger immune suppression than partial formulations in a longitudinal setting.
A prospective cohort study of 120 K/BxN mice receiving one of four nanoparticle variants, tracking immune markers weekly for 6 weeks, adjusting for baseline disease and genetic background.
Whether mice with the strongest immune suppression are more likely to have received the full nanoparticle design.
A case-control study comparing 30 mice with >50% reduction in arthritis score and >30% Treg increase (cases) to 30 with minimal change (controls), retrospectively assessing nanoparticle composition received.
Whether mice receiving the full nanoparticle design show stronger immune changes than those receiving partial versions at a single timepoint.
A cross-sectional comparison of immune markers in 20 mice per group (full, no CD22L, no rapamycin, no antigen) at day 28 post-treatment.